Go Pro

Morgan Stanley's Rating of InnoCare Pharma on 5/28/2026

On May 28, 2026, Morgan Stanley updated its outlook on InnoCare Pharma (OTCMKTS:INCPF) with the action "Upgrade", setting a "Overweight" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Morgan Stanley

DateCompanyAction
9/3/2026
Ashmore Group stock logo
AJMPF
Ashmore Group
Reiterated Rating
9/3/2026
Galaxy Digital Inc. stock logo
GLXY
Galaxy Digital
Boost Price Target
9/3/2026
Netskope Inc. stock logo
NTSK
Netskope
Boost Price Target
9/3/2026
Broadcom Inc. stock logo
AVGO
Broadcom
Reiterated Rating
9/3/2026
Snowflake Inc. stock logo
SNOW
Snowflake
Boost Price Target
9/3/2026
flatexDEGIRO AG stock logo
FNNTF
flatexDEGIRO
Upgrade
More Ratings From Morgan Stanley